Diagnostic kits are crucial for
tracking and treating diseases. In this edition of CSO series, BioSpectrum
highlights the achievements of Dr
Shama Bhat, founder and chairman of Bhat Bio-Tech; and Dr Pradip Desai,
founder and chairman of Span Diagnostics
![](/IMG/071/47071/femaledoctorshandcheckin.jpg)
Diagnosis is the first step in identifying the
cause of any disease. Hence correct diagnosis is an obvious
pre-requisite for planning any strategy for prevention, treatment or
mitigation of diseases; increasing the effectiveness of treatment; and
reducing the therapeutic turnaround time. Furthermore, diagnosis is
also performed to reduce uncertainty related to a suspected disease
condition.
A fairly confident diagnosis can sometimes be made on the basis of
clinical signs or symptoms alone, but accurate diagnosis usually
requires a specific diagnostic test, often involving access to a
diagnostic laboratory. Diagnostic tests have a key role in patient
management and identifying most appropriate antibiotic to be used for
treatment of infectious diseases. As compared to earlier times when the
patients were treated on the basis of clinical symptoms, today doctors
are equipped with diagnostic results to find out the root cause of any
disease. This also helps the doctor to track the disease progression
and relapse.
Therefore, to offer cost-effective diagnostics solutions for people in
resource-poor areas, developing and launching diagnostics for world's
neglected diseases such as tuberculosis, syphilis, cholera, filaria,
kala-azar, plague and malaria is a great responsibilty.
The diagnostic companies in India have come a long way over the
decades. There are a lot of indigenous companies that have made a
significant difference in the diagnostic sector. Companies such as Bhat
Bio-Tech, Span Diagnostics, Tulip Diagnostics and XCyton Diagnostics
are the few prominent names in this space. The total number of clinical
laboratories in India is said to be in between 38,000 and 40,000.
Companies such as Bhat Bio-Tech have developed innovative methods to
cut down the cost by using indigenous reagents. For example, for making
the HIV kits we need HIV antigens. HIV antigens imported from the US
will cost about $123 (
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
5,500) per mg. To make the same antigen
in-house, it will cost less than $2.2 (
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
100) per mg. When Bhat Bio-Tech
started marketing pregnancy kits in 1996, it was priced at $1.1 (
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
50)
per test to the distributors and now it is being sold at less than
$0.15 (
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
7) per test.
Similarly, another example is of Span Diagnostics, which has been
supplying the HIV test kits for National AIDS Control Program for the
last eight years and malaria test kits for Malaria Control Program for
the last five years.
However, it is also evident that in-vitro diagnostics (IVD) accounts
for only three percent of overall healthcare spending.
Dr. Shama Bhat
Dr Pradip K. Desai